166324-47-6

Upstream product

• 113140-81-1 5-methyl-1-(triphenylmethyl)-1H-imidazole-4-carboxaldehyde 
• 138476-60-5 8,9-dihydro-7-[(hydroxy)-(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]-indol-6(7H)-one 
• 91486-91-8 <2-(2,6-dioxopiperidin-1-yl)phenylmethyl>triphenylphosphonium bromide 
• 91486-93-0 6,7,8,9-tetrahydropyrido[1,2-a]indol-6-one 
• 129299-94-1 7-[(acetoxy)-(5-methyl-1-trityl-1H-imidazol-4-yl)methyl]-8,9-dihydropyrido[1,2-a]indol-6(7H)-one 

Downstream Products

• 129299-72-5 (+/-)-8,9-dihydro-10-methyl-7-<(5-methyl-1H-imidazol-4-yl)methyl>pyrido<1,2-a>indol-6(7H)-one 

Relevant academic research and scientific papers

New 5-HT3 (serotonin-3) receptor antagonists. III. An efficient synthesis of carbon 14-labeled (+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4- yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride (FK 1052).

(+)-8,9-Dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4- yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride (FK 1052, 1) is a highly potent 5-HT3 (serotonin-3) receptor antagonist. For the study of the metabolism and disposition of FK 1052 (1), we synthesized carbon 14-labeled FK 1052 in three steps from 10-demethyl FK 1052 (8). The Mannich reaction and subsequent hydrogenolysis of the dimethylaminomethyl group enabled the efficient introduction of one carbon atom at the 10-position of the pyrido[1,2-a]indol-6,(7H)-one ring. The Mannich reaction of (+)-8,9-dihydro-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2- ]indol-6(7H)-one (8) with [14C]paraformaldehyde and dimethylamine hydrochloride gave the [14C]-10-dimethylaminomethyl compound (20). Subsequent hydrogenolysis of 20 with palladium on carbon and ammonium formate, followed by recrystallization of the salt with (+)-di-p-toluoyl-D-tartaric acid, gave [14C]FK 1052 with a radiochemical purity of 99.4% and an enantiomeric excess of more than 97%.

New 5-HT3 (serotonin-3) receptor antagonists, I. Synthesis and structure-activity relationships of pyrido[1,2-a]indoles

A series of pyrido[1,2-a]indol-6(7H)-ones was prepared and evaluated for 5-HT3 receptor antagonist activity. The structural requirements for the 5-HT3 receptor antagonist have been defined as an aromatic moiety, a basic nitrogen, and

Pyridoindole derivatives and processes for preparation thereof

Compounds of the formula: STR1 wherein R 1 is hydrogen, lower alkyl or lower alkenyl, R 2 is hydrogen, lower alkyl, or halogen, R 3 is imidazolyl or pyridyl, each of which may have suitable substituents, and R 4 is hydrogen, lower alkyl, lower alkenyl or